Unmet needs in HF


Increasing awareness to inspire action

Deficiency in heart failure (HF) awareness is a universal problem. There are significant gaps in the understanding of HF and the burden it places on healthcare systems and society.

Everyone – from patients and healthcare providers to policymakers and the public – needs to know that every person with HF, regardless of symptoms, remains at risk for a cardiovascular event.


A significant unmet need

Even with current HF standard of care, nine out of ten patients remain symptomatic and are still at risk of hospitalisation for HF and cardiovascular death.1*

Patients with HF with reduced ejection fraction (HFrEF), including those who may appear stable, have an unacceptably high risk of hospitalisation and even death2


Of patients Experienced CV death or hospitalisation based on NYHA Class II classification, studied over a 4-year period

CHaRM-HF Study, 2003

A substantial human and economic burden


Hospitalisation for HF is associated with tremendous healthcare costs, which will continue to rise.4



A grim prognosis

Hospitalisation for HF can increase mortality and lead to death.

Each hospitalisation for heart failure (hHF), from the very first, is a setback to survival that should be avoided.6‡


A call to action

patients with heart failure will die within 5 years after diagnosis.7


Intervening with comprehensive HF management today may save more lives tomorrow.8


HF demands more attention, from patients, healthcare providers, policymakers and the public. The World Heart Federation and AstraZeneca have partnered on the Spotlight On Heart Failure campaign to provide much-needed education about HF and improve the prognosis for those who have been diagnosed.

Help accelerate change in HF

*Based on a US prospective observational study of 3,494 US outpatients with chronic HFrEF in the CHAnge the Management of Patients with Heart Failure (CHAMP-HF) registry.1
Based on a retrospective analysis of 51,286 patients from a US Military Data Repository admitted to a health care facility for the first time for heart failure. During the 7-year study period (2007-2013), patients were assessed for subsequent hHF, comorbidities, and mortality data. No distinction was made between patients with reduced or preserved ejection fraction.6


  1. Khariton Y, Nassif ME, Thomas L, et al. Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. JACC Heart Fail. 2018;6(6):465-473.
  2. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618-2626.
  3. Díez-Villanueva P, Alfonso F. Heart failure in the elderly. J Geriatr Cardiol. 2016;13(2):115-117.
  4. Cowie MR. Presentation at the 2nd World Congress on Acute Heart Failure; 23–26 May 2015; Seville, Spain.
  5. Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.
  6. Lin AH, Chin JC, Sicignano NM, et al. Repeat Hospitalisations Predict Mortality in Patients With Heart Failure. Mil Med. 2017;182(9):e1932-e1937.
  7. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-e322.
  8. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121-128.